Observational studyFrontiers in endocrinology2026
Thyroid hormone replacement is associated with improvement in renal dysfunction in patients with hypothyroidism: a retrospective observational study.
Observational study in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypothyroidism is a common endocrine disorder with multisystem involvement and is increasingly recognized as a potentially reversible contributor to renal dysfunction. However, renal impairment related to thyroid hormone deficiency is frequently overlooked or misclassified as chronic kidney disease in clinical practice. Methods: In this single-center retrospective observational study, 40 hospitalized adults with newly diagnosed hypothyroidism were included. Renal dysfunction was defined by elevated serum creatinine and reduced estimated glomerular filtration rate at admission. All patients received levothyroxine replacement therapy as part of routine care. Biochemical parameters were assessed at three timepoints: admission (T0), normalization of thyroid-stimulating hormone (T1), and normalization of serum creatinine (T2). Serum creatinine was the primary renal outcome, whereas estimated glomerular filtration rate was evaluated as a supportive calculated indicator. Secondary outcomes included thyroid hormones and other biochemical markers. Results: At baseline, mean serum creatinine was 114.88 ± 25.61 μmol/L and estimated glomerular filtration rate was 51.42 ± 16.32 mL/min/1.73 m². Following treatment, serum creatinine decreased significantly to 85.13 ± 21.01 μmol/L at T1 and 79.92 ± 5.64 μmol/L at T2 (both P < 0.01). Estimated glomerular filtration rate improved to 74.48 ± 32.56 and 75.04 ± 14.52 mL/min/1.73 m², respectively. Free thyroid hormone levels increased, while other biochemical parameters showed no consistent changes. Analyses at T1 and T2 were based on responder subgroups that achieved predefined biochemical targets. Conclusion: Thyroid hormone replacement was associated with significant short-term improvement in creatinine-based renal indices, suggesting that renal dysfunction in hypothyroidism may be at least partially functional and potentially reversible in some patients. These findings should be interpreted cautiously given the small sample size, retrospective design, responder-based subgroup analyses, absence of a comparison group, and potential residual confounding.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.